Challenging hypertension: How to diagnose and treat resistant hypertension in daily clinical practice

Expert Review of Cardiovascular Therapy

Volumn 8, Issue 6, 2010, Pages 811-820

  Volpe, Massimo ^a,b   Tocci, Giuliano ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS NEUROMED   (Italy)

Author keywords

Antihypertensive treatment; Blood pressure control; Clinical inertia; Refractory hypertension; Resistant hypertension

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ALDOSTERONE ANTAGONIST; ALISKIREN; AMLODIPINE; ANOREXIGENIC AGENT; ANTIANEMIC AGENT; ANTIHYPERTENSIVE AGENT; ATENOLOL; CANRENOATE POTASSIUM; CANRENONE; CHLORTALIDONE; CLONIDINE; CYCLOSPORIN; DIURETIC AGENT; DOXAZOSIN; ENALAPRIL; ENDOTHELIN RECEPTOR ANTAGONIST; EPLERENONE; GLUCOCORTICOID; LERCANIDIPINE; LISINOPRIL; NONSTEROID ANTIINFLAMMATORY AGENT; OMAPATRILAT; POTASSIUM SPARING DIURETIC AGENT; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT;

BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL PRACTICE; DIASTOLIC BLOOD PRESSURE; DRUG ABUSE; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; LIFESTYLE MODIFICATION; PATHOPHYSIOLOGY; PREVALENCE; RESISTANT HYPERTENSION; REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; ADRENERGIC SYSTEM; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; CLASSIFICATION; DIFFERENTIAL DIAGNOSIS; DRUG COMBINATION; DRUG EFFECTS; PHYSIOLOGY; PRACTICE GUIDELINE; RENAL INSUFFICIENCY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; DIAGNOSIS, DIFFERENTIAL; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; KIDNEY FAILURE; PRACTICE GUIDELINES AS TOPIC; RENIN-ANGIOTENSIN SYSTEM; SYMPATHETIC NERVOUS SYSTEM; TREATMENT OUTCOME; RENAL INSUFFICIENCY;

EID: 77953503338     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.10.47     Document Type: Review

References (69)

1. Staessen JA, Wang J, Bianchi G, Birkenhager WH. Essential hypertension. Lancet 361(9369), 1629-1641 (2003).
2. Kearney PM, Whelton M, Reynolds K et al. Global burden of hypertension: analysis of worldwide data. Lancet 365(9455), 217-223 (2005).
3. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 362(9395), 1527-1535 (2003).
4. Turnbull F, Neal B, Algert C et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch. Intern. Med. 165(12), 1410-1419 (2005).
5. Kotseva K, Wood D, De Backer G et al. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 373(9667), 929-940 (2009).
6. Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 25(6), 1105-1187 (2007). (Pubitemid 46924065)
7. Lenfant C, Chobanian AV, Jones DW, Roccella EJ. Seventh report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7): resetting the hypertension sails. Hypertension 41(6), 1178-1179 (2003).
8. Williams B, Poulter NR, Brown MJ et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. Br. Med. J. 328(7440), 634-640 (2004). (Pubitemid 38340037)
9. Palmer BF. Improving BP control with combined renin-angiotensin system blockade and thiazide diuretics in hypertensive patients with diabetes mellitus or kidney disease. Am. J. Cardiovasc. Drugs 8(1), 9-14 (2008).
10. Struijker-Boudier HA, Ambrosioni E, Holzgreve H et al. The need for combination antihypertensive therapy to reach target blood pressures: what has been learned from clinical practice and morbidity-mortality trials? Int. J. Clin. Pract. 61(9), 1592-1602 (2007).
11. Wolf-Maier K, Cooper RS, Banegas JR et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 289(18), 2363-2369 (2003).
12. Sarafidis PA, Bakris GL. Resistant hypertension: an overview of evaluation and treatment. J. Am. Coll. Cardiol. 52(22), 1749-1757 (2008).
13. Calhoun DA, Jones D, Textor S et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 51(6), 1403-1419 (2008).
14. Whyte JL, Lapuerta P, L'Italien GJ, Franklin SS. The challenge of controlling systolic blood pressure: data from the National Health and Nutrition Examination Survey (NHANES III), 1988-1994. J. Clin. Hypertens. (Greenwich) 3(4), 211-216 (2001).
15. Wolf-Maier K, Cooper RS, Kramer H et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 43(1), 10-17 (2004).
16. Cooper RS, Wolf-Maier K, Luke A et al. An international comparative study of blood pressure in populations of European vs. African descent. BMC Med. 3, 2 (2005).
17. Boersma E, Keil U, De Bacquer D et al. Blood pressure is insufficiently controlled in European patients with established coronary heart disease. J. Hypertens. 21(10), 1831-1840 (2003).
18. Volpe M, Tocci G, Trimarco B et al. Blood pressure control in Italy: results of recent surveys on hypertension. J. Hypertens. 25(7), 1491-1498 (2007).
19. Gorostidi M, Sobrino J, Segura J et al. Ambulatory blood pressure monitoring in hypertensive patients with high cardiovascular risk: a cross-sectional analysis of a 20,000-patient database in Spain. J. Hypertens. 25(5), 977-984 (2007).
20. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288(23), 2981-2997 (2002).
21. Tocci G, Giovannelli F, Sciarretta S et al. Management of hypertension and stroke prevention: results of the Italian cardiologist survey. Int. J. Clin. Pract. 63(2), 207-216 (2009).
22. Volpe M, Notaro LA, Tocci G et al. The Reassessment of Antihypertensive Chronic Therapy (REACT) Study: an Italian observational study on hypertension management in patients with established therapy. High Blood Pressure & Cardiovascular Prevention 11(4), 175-185 (2004).
23. Mancia G, Parati G, Pomidossi G et al. Alerting reaction and rise in blood pressure during measurement by physician and nurse. Hypertension 9(2), 209-215 (1987).
24. Borghi C, Dormi A, D'Addato S, Gaddi A, Ambrosioni E. Trends in blood pressure control and antihypertensive treatment in clinical practice: the Brisighella Heart Study. J. Hypertens. 22(9), 1707-1716 (2004). (Pubitemid 39141962)
25. Verdecchia P, Staessen JA, White WB, Imai Y, O'Brien ET. Properly defining white coat hypertension. Eur. Heart J. 23(2), 106-109 (2002).
26. Mancia G, Bombelli M, Facchetti R et al. Long-term risk of sustained hypertension in white-coat or masked hypertension. Hypertension 54(2), 226-232 (2009).
27. Veglio F, Rabbia F, Riva P et al. Ambulatory blood pressure monitoring and clinical characteristics of the true and white-coat resistant hypertension. Clin. Exp. Hypertens. 23(3), 203-211 (2001).
28. Brown MA, Buddle ML, Martin A. Is resistant hypertension really resistant? Am. J. Hypertens. 14(12), 1263-1269 (2001).
29. Rossi GP, Seccia TM, Pessina AC. Clinical use of laboratory tests for the identification of secondary forms of arterial hypertension. Crit. Rev. Clin. Lab. Sci. 44(1), 1-85 (2007).
30. Locatelli F, Manzoni C, Marcelli D. Treatment of hypertension in chronic renal insufficiency. J. Nephrol. 10(4), 220-223 (1997).
31. Fournier A, el Esper N, Makdassi R et al. Hypertension and progression of renal insufficiency. Nephrol. Dial. Transplant. 9(Suppl. 3), 28-34 (1994).
32. London GM, Guerin AP, Pannier B, Marchais SJ, Safar ME. Large artery structure and function in hypertension and end-stage renal disease. J. Hypertens. 16(12 Pt 2), 1931-1938 (1998).
33. Brown MA, Whitworth JA. Hypertension in human renal disease. J. Hypertens. 10(8), 701-712 (1992).
34. Gonzaga CC, Calhoun DA. Resistant hypertension and hyperaldosteronism. Curr. Hypertens. Rep. 10(6), 496-503 (2008).
35. Chun TY, Pratt JH. Hyperaldosteronism: a commonly occurring underlying feature of essential hypertension and the metabolic syndrome? Curr. Opin. Endocrinol. Diabetes Obes. 14(3), 210-212 (2007).
36. Moser M, Setaro JF. Clinical practice. Resistant or difficult-to-control hypertension. N. Engl. J. Med. 355(4), 385-392 (2006).
37. Douma S, Petidis K, Doumas M et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 371(9628), 1921-1926 (2008).
38. Kittisupamongkol W. Secondary causes of resistant hypertension. Arch. Intern. Med. 169(7), 717 (2009).
39. Pimenta E, Calhoun DA, Oparil S. Sleep apnea, aldosterone, and resistant hypertension. Prog. Cardiovasc. Dis. 51(5), 371-380 (2009).
40. Baguet JP, Levy P, Barone-Rochette G et al. Masked hypertension in obstructive sleep apnea syndrome. J. Hypertens. 26(5), 885-892 (2008). (Pubitemid 351520975)
41. de Leeuw PW, Gaillard CA, Birkenhager WH. Drug-induced hypertension. Neth. J. Med. 43(Suppl. 1), S39-S43 (1993).
42. Berecek KH, Farag A, Bahtiyar G, Rothman J, McFarlane SI. Adding low-dose spironolactone to multidrug regimens for resistant hypertension. Curr. Hypertens. Rep. 6(3), 211-212 (2004).
43. Lane DA, Beevers DG. Amiloride 10 mg is less effective than spironolactone 25 mg in patients with hypertension resistant to a multidrug regime including an angiotensin-blocking agent. J. Hypertens. 25(12), 2515-2516 (2007).
44. George J, Struthers AD. Evaluation of the aldosterone-blocking agent eplerenone in hypertension and heart failure. Expert Opin. Pharmacother. 8(17), 3053-3059 (2007).
45. Antonio Costa J, Rodilla E, Perez-Lahiguera F, Maria Pascual J. Eplerenone in resistant hypertension with previous spironolactone intolerance. Med. Clin. (Barc.) 132(19), 756-757 (2009).
46. Hood SJ, Taylor KP, Ashby MJ, Brown MJ. The Spironolactone, Amiloride, Losartan, and Thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio. Circulation 116(3), 268-275 (2007).
47. Chapman N, Dobson J, Wilson S et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 49(4), 839-845 (2007).
48. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am. J. Hypertens. 16(11 Pt 1), 925-930 (2003).
49. Gaddam K, Pimenta E, Thomas SJ et al. Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. J. Hum. Hypertens. DOI: 10.1038/ jhh.2009.96 (2009) (Epub ahead of print).
50. Volpe M, Miele C, Haag U. Efficacy and safety of a stepped-care regimen using olmesartan medoxomil, amlodipine and hydrochlorothiazide in patients with moderate-to-severe hypertension: an open-label, long-term study. Clin. Drug Investig. 29(6), 381-391 (2009).
51. Volpe M, Brommer P, Haag U, Miele C. Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre study. Clin. Drug Investig. 29(1), 11-25 (2009).
52. Brachmann J, Ansari A, Mahla G, Handrock R, Klebs S. Effective and safe reduction of blood pressure with the combination of amlodipine 5 mg and valsartan 160 mg in hypertensive patients not controlled by calcium channel blocker monotherapy. Adv. Ther. 25(5), 399-411 (2008).
53. Calo LA, Bertipaglia L, Pagnin E et al. Effect of doxazosin on oxidative stress related proteins in essential hypertensive patients. Clin. Exp. Hypertens. 28(2), 181-188 (2006).
54. Pessina AC, Ciccariello L, Perrone F et al. Clinical efficacy and tolerability of a-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism. Nutr. Metab. Cardiovasc. Dis. 16(2), 137-147 (2006).
55. Campo C, Segura J, Roldan C et al. Doxazosin GITS versus hydrochlorothiazide as add-on therapy in patients with uncontrolled hypertension. Blood Press. Suppl. 2, 16-21 (2003).
56. Oparil S, Barr E, Elkins M et al. Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension. Clin. Ther. 18(4), 608-625 (1996). (Pubitemid 26323039)
57. Jamerson K, Weber MA, Bakris GL et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 359(23), 2417-2428 (2008).
58. Tocci G, Palano F, Pagannone E et al. Fixed-combination therapies in hypertension management: focus on enalapril/lercanidipine. Expert Rev. Cardiovasc. Ther. 7(2), 115-123 (2009).
59. Volpe M. Cardiovascular risk in hypertension - can we ask for more?: Focus on aliskiren. High Blood Pressure & Cardiovascular Prevention 15(4), 255-268 (2008).
60. Frampton JE, Curran MP. Aliskiren: a review of its use in the management of hypertension. Drugs 67(12), 1767-1792 (2007).
61. Bureik M, Hubel K, Dragan CA et al. Development of test systems for the discovery of selective human aldosterone synthase (CYP11B2) and 11b-hydroxylase (CYP11B1) inhibitors. Discovery of a new lead compound for the therapy of congestive heart failure, myocardial fibrosis and hypertension. Mol. Cell. Endocrinol. 217(1-2), 249-254 (2004).
62. Tikkanen T, Tikkanen I, Rockell MD et al. Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme in rats with hypertension and diabetes mellitus. Hypertension 32(4), 778-785 (1998).
63. Trippodo NC, Robl JA, Asaad MM et al. Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS- 182657 in experimental hypertension and heart failure. J. Pharmacol. Exp. Ther. 275(2), 745-752 (1995).
64. French JF, Anderson BA, Downs TR, Dage RC. Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase in rats with hypertension. J. Cardiovasc. Pharmacol. 26(1), 107-113 (1995).
65. Weber MA, Black H, Bakris G et al. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet 374(9699), 1423-1431 (2009).
66. Young KC, Teeters JC, Benesch CG, Bisognano JD, Illig KA. Cost-effectiveness of treating resistant hypertension with an implantable carotid body stimulator. J. Clin. Hypertens. (Greenwich) 11(10), 555-563 (2009).
67. Krum H, Schlaich M, Whitbourn R et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 373(9671), 1275-1281 (2009).
68. Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic-nerve ablation for uncontrolled hypertension. N. Engl. J. Med. 361(9), 932-934 (2009).
69. Frank H, Heusser K, Geiger H et al. Temporary reduction of blood pressure and sympathetic nerve activity in hypertensive patients after microvascular decompression. Stroke 40(1), 47-51 (2009).